Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Post-ASCO & EHA 2023 AML Highlights
20 June 2023 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in AML from ASCO and EHA 2023
Covering updates in newly diagnosed AML, FLT3, venetoclax-based regimens and IO/novel/early phase therapies
Session 1: Newly Diagnosed AML
Survival outcomes with CPX-351 vs 7+3: 5-yr follow-up study
Jorge Cortes Georgia Cancer Center, Augusta University, Augusta, GA, United States
Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk AML
Joshua Mitchell Washington University in St. Louis, St. Louis, MO, United States
Real-world data of CPX-351: CREST-UK post-hoc analysis
Priyanka Mehta University Hospitals of Bristol and Weston NHS Trust, Bristol, United Kingdom
ASCT among older pts treated with CLAD, LDAC plus Ven for AML
Jayastu Senapati The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion
Session 2: FLT3
Aza, Ven & Gilt for patients with FLT3m AML
Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States
QUIWI: Quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD AML
Pau Montesinos La Fe University Hospital, Valencia, Spain
BMT-CTN 1506 (MORPHO): Gilteritinib as post-transplant maintenance for FLT3-ITD AML
Mark Levis Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
Panel discussion
Session 3: Venetoclax-based regimens
VFLAI vs VFLAI & 3+7: A GIMEMA Italian cooperative analysis
Alfonso Piciocchi GIMEMA Foundation, Rome, Italy
SCT in older patients treated with ven + HMA therapies
Keith Pratz University of Pennsylvania, Philadelphia, PA, United States
Panel discussion
Session 4: IO/Novel/Early Phase
SAR443579 for R/R AML, B-ALL, HR-MDS
Anthony Stein City of Hope, Duarte, CA, United States
Bexmarilimab with SoC for myeloid malignancies
Mika Kontro University of Helsinki, Helsinki, Finland
Pivekimab Sunirine (PVEK, IMGN632) for BPDCN
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Ziftomenib for R/R NPM1-mutated AML
Amir Fathi Massachusetts General Hospital Cancer Center, Boston, MA, United States
Olutasidenib in post-Venetoclax Patients with mutant LDH1 AML
Jorge Cortes Georgia Cancer Center, Augusta University, Augusta, GA, United States
Panel discussion
The Post-ASCO & EHA 2023 AML Highlights webinar has been supported by:
Gold Supporters
